Lista de obras -

A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer ⬇️

artículo científico publicado el 19 de noviembre de 2010

A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer

artículo científico publicado en 2010

Alam K et al. (2018) Drug Metabolism Letters; 12, 24-32

artículo científico publicado en 2018

Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.

artículo científico publicado en 2014

Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial

artículo científico publicado en 2010

Androgen receptor sequence and variations in several common prostate cancer cell lines

artículo científico publicado en 2010

Androgen receptor variation affects prostate cancer progression and drug resistance

artículo científico publicado en 2016

Antiangiogenesis therapeutic strategies in prostate cancer

artículo científico publicado en 2002

Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer

artículo científico publicado en 2007

Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial

artículo científico publicado en 2016

BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer

artículo científico publicado en 2014

BETting on next-generation bromodomain inhibitors

scientific article published on 15 August 2020

Current status of thalidomide and its role in the treatment of metastatic prostate cancer

artículo científico publicado en 2003

Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.

artículo científico publicado en 2010

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.

artículo científico publicado en 2017

Disclosing a diagnosis of cancer: where and how does it occur?

artículo científico publicado en 2010

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells

artículo científico publicado en 2015

Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer

artículo científico publicado en 2008

Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease

artículo científico publicado en 2015

Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer

artículo científico publicado en 2014

Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy

artículo científico publicado en 2010

Expression of OATP Family Members in Hormone-Related Cancers: Potential Markers of Progression ⬇️

artículo científico publicado el 19 de mayo de 2011

Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial

artículo científico publicado en 2015

Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer

artículo científico publicado en 2010

Genetic variation: effect on prostate cancer.

artículo científico publicado en 2014

Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism

artículo científico publicado en 2004

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

artículo científico publicado en 2010

Impact of ABCB1 allelic variants on QTc interval prolongation

artículo científico publicado en 2010

Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer

artículo científico publicado en 2002

Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer

artículo científico publicado en 2005

Molecular alterations in primary prostate cancer after androgen ablation therapy

artículo científico publicado en 2005

Mutations in the EGFR: the importance of genotyping

artículo científico publicado en 2004

Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer

artículo científico publicado en 2017

Piecing together the HIF-1 puzzle: the role of the CTGF as a molecular mechanism of HIF-1 regulation

artículo científico publicado en 2006

Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer

artículo científico publicado en 2005

Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment

artículo científico publicado en 2016

Prostate cancer genomic signature offers prognostic value ⬇️

artículo científico publicado el 1 de diciembre de 2010

Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivation

artículo científico publicado en 2014

Racial Disparities in the Association Between Variants on 8q24 and Prostate Cancer: A Systematic Review and Meta-Analysis ⬇️

artículo científico publicado el 1 de enero de 2012

Sarcosine as a potential prostate cancer biomarker and therapeutic target

artículo científico publicado en 2010

Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study

artículo científico publicado en 2011

Significant addition to treatment options for bone metastasis in prostate cancer ⬇️

artículo científico publicado el 15 de enero de 2012

The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity ⬇️

artículo científico publicado el 16 de febrero de 2011

VEGF inhibition and metastasis: possible implications for antiangiogenic therapy

artículo científico publicado en 2009

hTert-immortalized endothelial cells: an important new research tool.

artículo científico publicado en 2004

Lista de obras de

A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer ⬇️

A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer

Alam K et al. (2018) Drug Metabolism Letters; 12, 24-32

Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.

Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial

Androgen receptor sequence and variations in several common prostate cancer cell lines

Androgen receptor variation affects prostate cancer progression and drug resistance

Antiangiogenesis therapeutic strategies in prostate cancer

Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer

Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial

BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer

BETting on next-generation bromodomain inhibitors

Current status of thalidomide and its role in the treatment of metastatic prostate cancer

Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.

Disclosing a diagnosis of cancer: where and how does it occur?

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells

Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer

Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease

Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer

Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy

Expression of OATP Family Members in Hormone-Related Cancers: Potential Markers of Progression ⬇️

Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial

Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer

Genetic variation: effect on prostate cancer.

Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

Impact of ABCB1 allelic variants on QTc interval prolongation

Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer

Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer

Molecular alterations in primary prostate cancer after androgen ablation therapy

Mutations in the EGFR: the importance of genotyping

Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer

Piecing together the HIF-1 puzzle: the role of the CTGF as a molecular mechanism of HIF-1 regulation

Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer

Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment

Prostate cancer genomic signature offers prognostic value ⬇️

Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivation

Racial Disparities in the Association Between Variants on 8q24 and Prostate Cancer: A Systematic Review and Meta-Analysis ⬇️

Sarcosine as a potential prostate cancer biomarker and therapeutic target

Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study

Significant addition to treatment options for bone metastasis in prostate cancer ⬇️

The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity ⬇️

VEGF inhibition and metastasis: possible implications for antiangiogenic therapy

hTert-immortalized endothelial cells: an important new research tool.